With Pfizer’s and Moderna’s vaccines proving highly protective against COVID-19 in large clinical trials, planning to roll out and distribute the two shots throughout the U.S. has kicked into high gear.
The vaccines are expected to be authorized shortly after FDA advisory committees review them — meetings are scheduled Dec. 10 for Pfizer’s candidate and Dec. 17 for Moderna’s — although the agency still needs to review the companies’ data and reach its decision.
Both companies have been working feverishly to manufacture the hundreds of millions of doses that will be needed, but supplies will be extremely limited in the months following any authorization.
